Kurma Partners Secures €215 Million for Biofund IV
Paris-based Kurma Partners has successfully closed its latest fund, Biofund IV, at an impressive €215 million. This significant achievement is backed by major investors including CSL, the European Investment Fund (EIF), and Bpifrance.
Reaching New Heights in Assets Under Management
The closing of Biofund IV brings Kurma Partners’ total assets under management to a remarkable €1 billion. This milestone follows the successful trade sales from their previous fund, Biofund III, which saw successful exits to prominent companies such as AstraZeneca, Eli Lilly, uniQure, and Ipsen.
Strategic Investments in the Biopharmaceutical Sector
With Biofund IV, Kurma Partners aims to continue its strategic investments in the biopharmaceutical sector, focusing on innovative companies that are poised for growth. The firm has established a reputation for identifying and nurturing startups that are leading the charge in healthcare innovation.
The support from institutional investors like CSL and EIF highlights the confidence in Kurma Partners’ investment strategy and their ability to deliver strong returns. As the biopharmaceutical landscape evolves, Kurma is well-positioned to capitalize on emerging opportunities and drive advancements in medical science.
Conclusion
With Biofund IV’s closure, Kurma Partners not only reinforces its commitment to fostering innovation in the biotech field but also establishes itself as a key player in the investment landscape. The firm’s growth trajectory suggests a bright future as they continue to support groundbreaking companies in their mission to improve global health.
Related
